GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hanall Biopharma Co Ltd (XKRX:009420) » Definitions » EV-to-Revenue

Hanall Biopharma Co (XKRX:009420) EV-to-Revenue : 8.93 (As of Jul. 03, 2025)


View and export this data going back to 1989. Start your Free Trial

What is Hanall Biopharma Co EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Hanall Biopharma Co's enterprise value is ₩1,259,364 Mil. Hanall Biopharma Co's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 was ₩141,000 Mil. Therefore, Hanall Biopharma Co's EV-to-Revenue for today is 8.93.

The historical rank and industry rank for Hanall Biopharma Co's EV-to-Revenue or its related term are showing as below:

XKRX:009420' s EV-to-Revenue Range Over the Past 10 Years
Min: 3.96   Med: 11.2   Max: 21.77
Current: 8.94

During the past 13 years, the highest EV-to-Revenue of Hanall Biopharma Co was 21.77. The lowest was 3.96. And the median was 11.20.

XKRX:009420's EV-to-Revenue is ranked worse than
85.6% of 965 companies
in the Drug Manufacturers industry
Industry Median: 2.44 vs XKRX:009420: 8.94

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2025-07-03), Hanall Biopharma Co's stock price is ₩25000.00. Hanall Biopharma Co's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2025 was ₩2,778.68. Therefore, Hanall Biopharma Co's PS Ratio for today is 9.00.


Hanall Biopharma Co EV-to-Revenue Historical Data

The historical data trend for Hanall Biopharma Co's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hanall Biopharma Co EV-to-Revenue Chart

Hanall Biopharma Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 20.64 9.83 7.72 16.24 13.95

Hanall Biopharma Co Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.19 11.77 14.45 13.95 9.80

Competitive Comparison of Hanall Biopharma Co's EV-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Hanall Biopharma Co's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hanall Biopharma Co's EV-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Hanall Biopharma Co's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Hanall Biopharma Co's EV-to-Revenue falls into.


;
;

Hanall Biopharma Co EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Hanall Biopharma Co's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=1259364.176/141000.353
=8.93

Hanall Biopharma Co's current Enterprise Value is ₩1,259,364 Mil.
Hanall Biopharma Co's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩141,000 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Hanall Biopharma Co  (XKRX:009420) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Hanall Biopharma Co's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=25000.00/2778.68
=9.00

Hanall Biopharma Co's share price for today is ₩25000.00.
Hanall Biopharma Co's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩2,778.68.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Hanall Biopharma Co EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Hanall Biopharma Co's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Hanall Biopharma Co Business Description

Traded in Other Exchanges
N/A
Address
12 Bongeunsa-ro 114-gil, Daewoong Building, 3rd Floor, Gangnam-gu, Seoul, KOR
Hanall Biopharma Co Ltd is a part of the healthcare sector. It is one of Korea's leading pharmaceutical companies and is focused on drug delivery, biotherapeutics, and new small molecule discovery. The company's scope comprises of ophthalmology, immunology, cardiovascular treatment and dermatology.

Hanall Biopharma Co Headlines

No Headlines